Table 3.
<50 days (n=1174)(%) |
50-100 days (n=950)(%) |
> 100 Days (n=371)(%) |
p value | |
---|---|---|---|---|
Age (years, median) | 64 | 66 | 65 | 0.05 |
Sex (female) | 156(13) | 160(17) | 54(15) | 0.07 |
Race | 0.52 | |||
White | 1131(98) | 914(97) | 357(98) | |
Black | 13(1) | 14(2) | 6(1.5) | |
Other | 14(1) | 10(1) | 1(0.5) | |
Year of diagnosis, median (inter-quartile range) | 2009(2007-2011) | 2010(2008-2012) | 2010(2008-2012) | <0.001 |
CDCC Score | 0.18 | |||
0 | 808(69) | 635(67) | 253(68) | |
1 | 307(26) | 244(26) | 91(25) | |
2+ | 59(5) | 71(8) | 27(7) | |
Insurance status | <0.001 | |||
Private | 551(48) | 367(40) | 126(35) | |
Government | 578(51) | 538(59) | 226(64) | |
None | 11(1) | 14(2) | 4(1) | |
Facility location | 0.88 | |||
Metro | 918(82) | 750(82) | 289(81) | |
Urban | 186(17) | 141(16) | 59(17) | |
Rural | 20(2) | 21(2) | 8(2) | |
Facility type | <0.001 | |||
Academic/research program | 671(58) | 614(65) | 258(70) | |
Pathologic stage | 0.39 | |||
1 | 818(81) | 689(83) | 262(83) | |
2 | 143(14) | 110(13) | 41(13) | |
3 | 51(5) | 28(3) | 11(4) | |
Path N stage | 0.91 | |||
N0 | 848(72) | 701(74) | 278(75) | |
N1 | 115(10) | 91(10) | 32(9) | |
N2 | 16(1) | 8(1) | 4(1) | |
N3 | 3(0.3) | 6(1) | 2(1) | |
Unknown | 192(16) | 144(15) | 55(15) | |
Tumor size (median mm with IQR) | 17(10-30) | 15(7-25) | 14(7-25) | <0.001 |
Positive margins | 0.12 | |||
R0 | 1097(97) | 900(98) | 349(97) | |
R1 | 19(2) | 8(1) | 3(1) | |
R2 | 1(0.1) | 0(0) | 2(0.6) | |
Unspecified positive | 13(1) | 7(1) | 2(0.6) | |
Indeterminate | 6(0.5) | 3(0.3) | 3(0.8) | |
Time to surgery (days)(median with IQR) | 34(23-42) | 69(59-81) | 128(112-162) | <0.001 |